COMMUNIQUÉS West-GlobeNewswire

Capsa Healthcare Acquires BlueBin to Advance Intelligent Clinical Supply Management
04/08/2025
Strategic acquisition integrates predictive analytics and Kanban methodology with point-of-care solutions to streamline supply operations and support clinical care delivery COLUMBUS, Ohio, Aug. 04, 2025 (GLOBE NEWSWIRE [...]
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models
04/08/2025
The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading [...]
Orion Corporation: Managers’ transactions – Satu Ahomäki
04/08/2025
ORION CORPORATION MANAGERS’ TRANSACTIONS 4 August 2025 at 16:10 EEST Orion Corporation: Managers’ transactions – Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
PracticeLink Announces Strategic Partnership with 3RNET
04/08/2025
Partnership reaffirms PracticeLink and 3RNET’s shared commitment to place physicians and healthcare providers in rural and underserved communities ST. LOUIS and HINTON, West Virginia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- [...]
Freya Pharma Solutions Announces Launch of Phase II Clinical Dose-Response Study testing its LybridoTM Concept Targeting Female Sexual Dysfunction
04/08/2025
www.freyapharmasolutions.com Study evaluates Lybrido™’s Dual-Action therapy for Female Sexual Dysfunction Innovative clitoral blood flow measurement technique aims to objectively quantify treatment efficacy of two dose- [...]
Clynt Reddy Joins MATTER Board of Directors
04/08/2025
Minneapolis, MN, Aug. 04, 2025 (GLOBE NEWSWIRE) -- MATTER, a Minnesota-based global NGO, is pleased to announce the appointment of Clynt Reddy to its Board of Directors. Reddy currently serves as the Executive Pastor at [...]
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
04/08/2025
BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of [...]
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
04/08/2025
Data Demonstrate that Sana’s Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to [...]
CROSSJECT reste mobilisé pendant la coupure estivale
04/08/2025
Communiqué de Presse CROSSJECT reste mobilisé pendant la coupure estivale Les opérations de maintenance sont déployées sur les sites de production. Les activités réglementaires et de développement se poursuivent [...]
CROSSJECT remains engaged during the summer break
04/08/2025
Press Release CROSSJECT remains engaged during the summer break Maintenance operations are being carried out at production sites. Regulatory and development activities are continuing actively. Dijon, France, August 4, [...]
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
04/08/2025
WARREN, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Accumulus Synergy Spins Out Accumulus Technologies to Scale Proven Regulatory Platform and Accelerate Global Access to Therapies
04/08/2025
BURLINGAME, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- In a bold move to accelerate regulatory innovation and meet growing global demand, Accumulus Synergy, a nonprofit industry association, today announced the formation [...]
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
04/08/2025
WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
04/08/2025
Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY ® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and [...]
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
04/08/2025
Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Conference call to be [...]
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
04/08/2025
BOSTON, Mass., and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have [...]
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
04/08/2025
BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered [...]
Atavistik Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ATV-1601 in Patients with AKT1 E17K-mutant Solid Tumors
04/08/2025
ATV-1601 is a first-in-class allosteric selective inhibitor of AKT1 E17K Pan-AKT inhibitors offer limited efficacy for patients with AKT1 E17K-driven mutant tumors due to insufficient inhibition of the AKT1 E17K [...]
OraSure Appoints Anne Messing as Chief Commercial Officer
04/08/2025
BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing [...]

Pages